Journal of Biological Chemistry · 2008 · 119 citations · 35 references
Life SciencesMolecular BiologyPharmacologyApoptosisChemotherapyGene ExpressionCell Cycle PharmacologyEnzyme InductionEnzyme InhibitionMetabolic ReprogrammingNucleotide MetabolismCell Cycle Arrest MechanismsImmunosuppressive CompoundsMycophenolic Acid TherapyNucleolar BiogenesisNucleolar FunctionNucleolar StressP53-mediated Cell-cycle ArrestRate-limiting Enzymes
Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is widely used as an immunosuppressive agent. MPA selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a rate-limiting enzyme for the de novo synthesis of guanine nucleotides, leading to depletion of the guanine nucleotide pool. Its chemotherapeutic effects have been attributed to its ability to induce cell cycle arrest and apoptosis. MPA treatment has also been shown to induce and activate p53. However, the mechanism underlying the p53 activation pathway is still unclear. Here, we show that MPA treatment results in inhibition of pre-rRNA synthesis and disruption of the nucleolus. This treatment enhances the interaction of MDM2 with L5 and L11. Interestingly, knockdown of endogenous L5 or L11 markedly impairs the induction of p53 and G(1) cell cycle arrest induced by MPA. These results suggest that MPA may trigger a nucleolar stress that induces p53 activation via inhibition of MDM2 by ribosomal proteins L5 and L11.
35
Regulation of HDM2 activity by the ribosomal protein L11
Marion Lohrum, Robert L. Ludwig, Michael H.G. Kubbutat et al. · Cancer Cell · 2003 · 616 citations · Full text